Keywords: Prostate, Prostate, APT; MRI; prostate cancer
Motivation: It has been reported amide proton transfer (APT) weighted MRI can differentiate clinically significant prostate cancer (csPCa), but its added value to PI-RADS remains uncertain.
Goal(s): Investigating if APT weighted MRI can provide added value to PI-RADS v2.1 in diagnosing csPCa.
Approach: 134 participants were enrolled. They were additionally imaged with APT weighted MRI before pathological examination. APT and apparent diffusion coefficient (ADC) values of lesion were analyzed.
Results: APT, ADC, and PI-RADS can significantly differentiate csPCa from non-csPCa. Compared with using PI-RADS alone, the combination of APT and PI-RADS can significantly improve the diagnostic performance.
Impact: Accurately diagnosing csPCa patients is important for treatment selection. APT weighted MRI can provide significantly added value to PI-RADS v2.1 for identifying csPCa. Therefore, the application of APT weighted MRI would be beneficial for prostate cancer assessment and management.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords